Occlusive dressing therapy using dimethyl sulfoxide in a patient presenting with primary localized amyloidosis of the urinary bladder: a case report
© Yoshino et al.; licensee BioMed Central Ltd. 2013
Received: 6 March 2013
Accepted: 5 June 2013
Published: 26 July 2013
Amyloidosis is characterized by extracellular deposition of abnormal insoluble fibrils, which cause structural and functional disorders. Amyloidosis is classified into primary and secondary disease. We report a case of localized amyloidosis of the urinary bladder. In the English literature, this is the first case effectively treated with occlusive dressing therapy using dimethyl sulfoxide.
A 58-year-old Japanese woman was introduced to our department with asymptomatic gross hematuria. Cystoscopy revealed a gently raised nodule at the right lateral wall. Histopathological findings of this lesion revealed extensive amorphous eosinophilic deposits that stained positive with Congo red and Dylon. The patient was diagnosed with primary localized amyloidosis of the urinary bladder. To treat residual amyloidosis of the bladder, we performed occlusive dressing therapy using dimethyl sulfoxide. After treatment, cystoscopy and magnetic resonance imaging showed no relapse of the mass-like lesion of the bladder wall.
Occlusive dressing therapy using dimethyl sulfoxide is efficacious and tolerable for amyloidosis of the urinary bladder. The maneuver of occlusive dressing therapy was simpler and easier than that of intravesical instillation, and occlusive dressing therapy was advantageous in that the patient could perform the therapy herself every day. However, invasive surgical management including cystectomy should be considered if conservative management is inefficacious.
KeywordsAmyloidosis Dimethyl sulfoxide Occlusive dressing therapy
Amyloidosis is a heterogenous group of diseases that share the common feature of extracellular deposition of an insoluble fibrillar protein in organs and tissues. Amyloidosis can also be classified as primary or secondary disease. The primary type (AL amyloidosis) is associated with an underlying immune dyscrasia, including multiple myeloma or Waldenström’s macroglobulinemia. In the secondary type (AA amyloidosis), an underlying chronic inflammatory disease often arises as a complication. Primary localized amyloidosis of the urinary bladder is a rare condition with approximately 200 reported cases in the literature [1–3]. The clinical presentation and cystoscopic appearance of this condition are known to mimic bladder cancer.
This was followed by biopsies of the stomach, duodenum and rectum, all of which were negative for amyloid. There was no Bence-Jones proteinuria, and serum or urine protein electrophoresis did not reveal any monoclonal band. Therefore, the patient was diagnosed with primary localized amyloidosis of the urinary bladder.
To treat residual amyloidosis of the bladder, we performed occlusive dressing therapy (ODT) using dimethyl sulfoxide (DMSO) every day. After percutaneous administration of DMSO, regression of the bladder lesions as well as improvement of gross hematuria were achieved. Five years after the initiation of treatment, cystoscopy and MRI showed no relapse of the mass-like lesion of the bladder wall. Currently, DMSO is administered every few days as maintenance therapy.
Amyloidosis is characterized by the extracellular deposition of proteins. Amyloidosis may be primary or secondary depending on whether it is due to underlying immune dyscrasia or secondary to a chronic inflammatory disorder. Although systemic amyloid can occur anywhere in the urinary tract, including the kidney, renal pelvis, ureter, urethra or corpora, primary localized amyloidosis of the urinary bladder is a rare urological disease [4–6].
Amyloidosis of the urinary bladder affects males and females equally in about the fifth and sixth decades of life. Previous studies have reported gross painless hematuria as the most common presentation and have stated that the remaining patients present with irritative voiding symptoms [4–6]. Primary amyloidosis of the urinary bladder assumes clinical importance because it clinically masquerades as a malignancy as in the present case.
Histological examination of the lesion is mandatory for diagnosis. Typically, primary amyloidosis deposits are superficially beneath the surface mucosa, sometimes extending into the superficial smooth muscle of the urinary bladder. In secondary amyloidosis, the amyloid tends to accumulate in the bladder vasculature thus explaining why secondary amyloidosis with diffuse bladder involvement has a high mortality of 30% with its potential for massive hemorrhage .
Management of primary amyloidosis of the urinary bladder is mainly transurethral resection of the bladder if it is localized. Medical treatments such as intravesical instillation of DMSO have also been tried with limited success.
DMSO is a dipolar solvent, which has a molecular weight of 78.13. DMSO has the action of penetrance acceleration, local anesthetic effect, sedative action and anti-inflammatory effect as pharmacological action. The penetrance action of DMSO is characteristic and it passes with a high concentration quickly through a skin barrier. Isobe  reported that when 90% DMSO solution was applied to human skin, it was identified in the blood 5 minutes later, and maximum blood concentration was obtained 4 to 6 hours later. In addition, this plateau was reported to last 36 to 72 hours . The internal use, application to the skin and enema administration have been tried successfully since the efficacy of DMSO for amyloidosis was reported by Osserman et al. in 1976 .
The intravesical instillation of DMSO has already been established in the treatment of amyloidosis of the urinary bladder . However, for this case, the cumbersome maneuver was considered to be a fault. The maneuver of ODT was simpler and easier than that of intravesical instillation, and ODT was advantageous in that the patient could herself make the ODT every day. In the present case, no severe side effects were observed and the treatment compliance of the case was good. Because there was no established theory about the duration of DMSO-ODT, the DMSO was administered every few days as maintenance therapy in our case. From now on we will extend intervals of administration gradually, monitoring for relapse of amyloidosis. There were less than 10 reported cases treated with ODT using DMSO for amyloidosis of the urinary bladder. Therefore, there is a need to accumulate data and demonstrate the optimum method of administration (concentration of solution, volume, application time) and the optimum duration of treatment.
In localized amyloidosis of the urinary tract, despite a few reports of recurrence, the prognosis is comparatively good. In addition, there were few cases of amyloidosis of the urinary bladder that required invasive surgical management such as cystectomy. Therefore, we think that conservative medical management such as ODT using DMSO should be tried first, leading to bladder preservation.
Invasive surgical management including cystectomy should be considered only if conservative management such as ODT using DMSO for several months does not induce a reduction of the bladder mass or improve gross hematuria.
ODT using DMSO is efficacious and tolerable for amyloidosis of the urinary bladder. The maneuver of ODT was simpler and easier than that of intravesical instillation. However, invasive surgical management including cystectomy should be considered if conservative management is inefficacious.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Merrimen JL, Alkhudair WK, Gupta R: Localized amyloidosis of the urinary tract: case series of nine patients. Urology. 2006, 67 (5): 904-909. 10.1016/j.urology.2005.11.029.View ArticlePubMedGoogle Scholar
- Javed A, Canales BK, Maclennan GT: Bladder amyloidosis. J Urol. 2010, 183 (6): 2388-2389. 10.1016/j.juro.2010.03.069.View ArticlePubMedGoogle Scholar
- Wilkinson M, Fanning DM, Flood H: Primary bladder amyloidosis. BMJ case rep. 2011, 20: 1-3.Google Scholar
- Malek RS, Wahner-Roedler DL, Gertz MA, Kyle RA: Primary localized amyloidosis of the bladder: experience with dimethyl sulfoxide therapy. J Urol. 2002, 168 (3): 1018-1020. 10.1016/S0022-5347(05)64564-8.View ArticlePubMedGoogle Scholar
- Caldamone AA, Elbadawi A, Moshtagi A, Frank IN: Primary localized amyloidosis of urinary bladder. Urology. 1980, 15 (2): 174-180. 10.1016/0090-4295(80)90416-1.View ArticlePubMedGoogle Scholar
- Biewend ML, Menke DM, Calamia KT: The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid. 2006, 13 (3): 135-142. 10.1080/13506120600876773.View ArticlePubMedGoogle Scholar
- Tirzaman O, Wahner-Roedler DL, Malek RS, Sebo TJ, Li CY, Kyle RA: Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc. 2000, 75 (12): 1264-1268. 10.4065/75.12.1264.View ArticlePubMedGoogle Scholar
- Isobe T: DMSO and amyloid—a new attempt at therapy of amyloidosis. Nihon Rinsho. 1979, 37 (9): 3278-3284.PubMedGoogle Scholar
- Osserman EF, Isobe T, Farhangi M: Effect of dimethyl sulfoxide (DMSO) in the treatment of amyloidosis. Amyloidosis. Edited by: Wegelius O, Pasternack A. 1976, New York: Academic Press, 553-564.Google Scholar
- Kato Y, Sue Y, Fujii H, Numata A, Yachiku S: Localized amyloidosis of the ureter and bladder treated effectively by occlusive dressing technique therapy using dimethyl sulfoxide: a case report. Hinyokika Kiyo. 2000, 46 (6): 421-424.PubMedGoogle Scholar
- Takeda T, Kozakai N, Ikeuchi K: Localized amyloidosis of the bladder treated effectively by occlusive dressing technique therapy using dimethyl sulfoxide (DMSO): two case reports. Nihon Hinyokika Gakkai Zasshi. 2005, 96 (7): 705-708.PubMedGoogle Scholar
- Matsugasumi T, Kamoi K, Harikai S, Inagaki T, Kimura Y, Hirahara N, Sou J, Nakagawa S, Kawauchi A, Miki T: Localized amyloidosis of the urinary bladder: a case report. Hinyokika Kiyo. 2011, 57 (8): 439-443.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.